I have read the prescribing information and it addresses the adjacent case but not this one.
I can parse the result. I am less sure what it licenses me to conclude.
I have deliberately not looked at anyone else’s interpretation yet.
What does this actually establish, and what does it not?
Put another way, escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
| Week | Fraction of steady state | Trough as × dose |
|---|---|---|
| 1 | 50 % | 0.50 |
| 2 | 75 % | 0.75 |
| 3 | 88 % | 0.88 |
| 4 | 94 % | 0.94 |
| 5 | 97 % | 0.97 |
| 6 | 98 % | 0.98 |
This is why a four-week step interval is approximately, but not exactly, steady state.
On the detail: the published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Slower costs time and nothing else. The ceiling is the same.
edited 11 Mar 2025 by Dr_Rosalind_Achebe — added the placebo-arm figures
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStart with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Concretely, titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Hold rather than escalate while symptoms are active. Always.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
The relevant detail is that the published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Stepping back is a normal adjustment, not a failure.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
The top of the schedule is not the target. The working dose is.
Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
The STEP programme escalated semaglutide over sixteen weeks in four-week steps to 2.4 mg weekly, and the trial-product estimand versus treatment-policy estimand distinction accounts for most of the difference between the figures quoted from those papers.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Four half-lives between steps, minimum. Work it out for your agent.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.